|
|
|
|
|
by mandevil
335 days ago
|
|
This is actually a lot harder than you think because we still don't understand gene therapy well enough to be able to be sure that any given treatment works without the really expensive part, the Randomized Control Trial. In 2017 a gene therapy was approved in the US for RPE65-associated Retinitis Pigmentosa, Luxterna, the first in-vivo gene therapy approved by the FDA (yay! List price was a mere 425,000/eye). Just a few months ago J&J announced that their gene therapy targeting a different gene, RPGR, missed its primary end-point, only 22 out of 55 treated patients showed improvements on at least two of the measures in the LUMEOS trial and there was no statistically significant improvement on their primary measure. That result happened even though this was mostly just "take the thing that already worked for Luxterna, and do a different gene." The problem is that the human body is far more complicated than computers, and does not scale the same way. This is why regulators are very wary of "Right to Try" type stuff, they want to be sure that medical treatments are actually effective before they are available to the broad public. These sorts of RCTs are still quite necessary, and they are the really expensive thing in drug discovery. (Well, it's both that they are expensive to run and also they kill all sorts of drugs that don't actually work.) |
|